SPOP and cancer: Importantly, by targeting the downstream effects of SPOP loss—particularly the accumulation of ZBTB3 and its upregulation of SHH—these therapies could address the unique oncogenic mechanisms in SPOP-mutant cancers, potentially improving patient outcomes with reduced off-target effects.